Revenue
$1.1b
Suppressed: metric quality flags mark this value as unsuitable for normal comparison.
The NZ$350m acquisition price from the Pacific Radiology Group acquisition is result context, not the main operating signal.
Revenue context before the current result.
Operating profit margin across covered periods.
Operating cash flow across covered periods.
Operating working-capital absorption or release by reporting period.
Key metrics
FY21 vs FY20
Revenue
$1.1b
Suppressed: metric quality flags mark this value as unsuitable for normal comparison.
Net profit after tax
−$49.2m
Suppressed: metric quality flags mark this value as unsuitable for normal comparison.
Net cash inflow from operating activities
$91.4m
n/m ↑ vs $0.02m
Final dividend per share
11.5c
-33.3% ↓ vs 17.3c
Profit before tax
−$91.8m
Suppressed: metric quality flags mark this value as unsuitable for normal comparison.
Cash and cash equivalents
$133.8m
Suppressed: metric quality flags mark this value as unsuitable for normal comparison.
Total assets
$9.5b
+25.7% ↑ vs $7.6b
What changed
Headline revenue grew n/m to $1.1b, but the comparison is distorted by discontinued-operations classification in both periods — event overlays confirm prior- and current-period reclassifications. The n/m reading is flagged unprecedented in Annolyse's historical baseline against a four-period range of -99.7% to 38.7%, but the move largely reflects which businesses sit in continuing versus discontinued, not underlying growth.
PBT swung from +$523.2m to -$91.8m (-117.6%) and NPAT from +$241.2m to -$49.2m (-120.4%), because the prior year captured $503.6m of Tilt Renewables Australasia result in continuing operations versus $71.6m this year, with discontinued operations now contributing $71.6m after tax.
Pre-lease free cash flow ran at -$368.4m on $459.8m of capex against $91.4m of operating cash flow — below normal range against a three-period mean of -$39.3m.
What matters
PBT growth of -117.6% sits at the lower edge of the four-period historical range. Stripping the prior-year Tilt-linked result from continuing operations, the underlying operating read is much narrower than the -$615m PBT swing suggests, which means the headline NPAT loss should not be taken as a clean indicator of operating deterioration.
Cash generation improved at the operating line but deteriorated at the free-cash-flow line. Operating cash flow climbed to $91.4m from effectively zero, yet capex of $459.8m (43.4% of revenue) produced pre-lease FCF of -$368.4m, $329.1m below the historical mean. This matters because it constrains how much of the dividend and growth investment is internally funded.
Segment results show real operational pressure beneath the reclassification noise. Trustpower NZ's result dropped to $30.8m from $97.7m and Wellington Airport's collapsed to $2.4m from $73.2m on COVID-affected aviation volumes. The dominant segment's earnings compression is invisible in the consolidated revenue line.
Expectations
That undershoot versus the company's own interim guide is the most concrete forward signal in this release and tempers any "trough is behind" reading.
HY21 captured 54.6% of full-year revenue and -56.5% of NPAT, implying second-half revenue of $480.8m and a second-half NPAT loss of $77.0m. The back half got worse on earnings, which matters because it pushes the recovery profile out rather than supporting a clean step-up into FY22.
Quality of result
The cleaner economic reads — Trustpower NZ, Wellington Airport, and pre-lease FCF — all point softer than the headline revenue line.
Operating cash flow of $91.4m is a genuine improvement on the near-zero prior base, but capex absorbs the entirety of it and then some, leaving pre-lease FCF at -$368.4m. Cash on hand of $133.8m and reduced net debt of $876.5m (from $3.2b) reflect announced asset-sale proceeds and capital raising rather than internally funded deleveraging, so the strengthened leverage direction should not be read as recurring operational cash generation.
The 11.5c final dividend is the current-period final component only and is described in release excerpts as a 4.5% increase on the prior final. It should not be compared directly against the 17.25c prior full-year total in the supplied per-share table.
Unresolved
This briefing cannot assess proportionate EBITDAF segment composition or net-debt covenant headroom without the detailed segment and debt-by-tranche disclosures.
Chat
Ask follow-up questions about Infratil's FY21 result.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Open to load segment breakdown.
Open to load analytical metrics.
Open to load key metrics.
company filing
FY21 / results announcementInfratil 2021 Annual Report
FY21 / financial reportInfratil Full Year Results for the year ended 31 March 2021
FY21 / results releaseInfratil FY2021 Results Presentation
FY21 / results presentationInfratil 2020 Annual Report
FY20 / financial reportcompany filing
HY21 / results announcementInfratil Group Interim Financial Statements to 30 September 2020
HY21 / financial reportInterim results announcement for the period ended 30 September 2020
HY21 / results releaseAgreement to acquire stake in Pacific Radiology Group unconditional
FY21 / commentaryInfratil announces agreement to acquire stake in Pacific Radiology Group
FY21 / commentaryRelated insights
Cross-company views selected from the metrics in this briefing.
Get the next Infratil briefing and related NZX reporting-season updates by email.